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ABSTRACT
Patients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations 
(TP53abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable 
clinical outcome. Chromosome 8 abnormalities, namely losses of 8p (8p−) and gains 
of 8q (8q+) have been suggested to aggravate the outcome of patients with TP53abs. 
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However, the reported series were small, thus hindering definitive conclusions. To 
gain insight into this issue, we assessed a series of 101 CLL patients harboring 
TP53 disruption. The frequency of 8p− and 8q+ was 14.7% and 17.8% respectively. 
Both were associated with a significantly (P < 0.05) higher incidence of a complex 
karyotype (CK, ≥3 abnormalities) detected by chromosome banding analysis (CBA) 
compared to cases with normal 8p (N-8p) and 8q (N-8q), respectively. In univariate 
analysis for 10-year overall survival (OS), 8p− (P = 0.002), 8q+ (P = 0.012) and CK 
(P = 0.009) were associated with shorter OS. However, in multivariate analysis only 
CK (HR = 2.47, P = 0.027) maintained independent significance, being associated 
with a dismal outcome regardless of chromosome 8 abnormalities. In conclusion, our 
results highlight the association of chromosome 8 abnormalities with CK amongst 
CLL patients with TP53abs, while also revealing that CK can further aggravate the 
prognosis of this aggressive subgroup. 
INTRODUCTION
The great majority (~80%) of patients with 
chronic lymphocytic leukemia (CLL) carry one of 
the chromosomal aberrations routinely analyzed by 
fluorescence in situ hybridization (FISH), namely deletions 
of 13q [del(13q)], 11q [del(11q)] and 17p [del(17p)] as 
well as trisomy 12. These aberrations are associated with 
distinct clinical outcome [1, 2]. In particular, del(17p) 
cases have the worst clinical outcome and the shortest 
overall survival (OS). Of note, it has been described that 
the remaining TP53 allele in del(17p) cases is generally 
mutated, although some CLL patients may harbor isolated 
TP53 mutations [3]. Taking into account both TP53 
deletions and mutations, the rate of TP53 aberrant CLL 
cases peaks at 10% at diagnosis [4, 5] and may even 
exceed 40% at disease progression, mainly in patients 
previously treated with chemotherapy [6]. In addition, 
genomic complexity detected by chromosome banding 
analysis (CBA) or genomic microarrays also predicting 
rapid disease progression, is correlated to TP53 disruption 
in a significant proportion of patients [7–9]. 
TP53 aberrations (TP53abs, namely del(17p) and/
or TP53 mutations) are associated with low response rates 
to standard chemoimmunotherapy [10]. Newly introduced 
signaling inhibitors represent a major advance for this 
group of patients, showing an improved overall response 
and progression-free survival even in refractory CLL cases 
[11–13]. 
Nonetheless, some CLL cases with TP53abs remain 
asymptomatic for extended periods of time, pointing 
to multiple associated genetic factors underlying the 
heterogeneity of this group of patients [14, 15]. 
Alterations of chromosome 8, and particularly losses 
of 8p (8p−, affecting several regions, from 8p11 to 8p23) 
and gains of 8q (8q+, usually involving 8q24, where 
MYC is located), have been suggested as new prognostic 
markers in CLL, even for patients harboring TP53abs. 
Although initial microarray studies identified chromosome 
8 alterations in around 5% of the general CLL population, 
subsequent analyses detected an increased frequency in 
patients with del(17p), ranging from 28 to 80%; 8p− and 
8q+ alterations were frequently concomitant and displayed 
an independent correlation with a shorter OS [16–21]. 
However, due to the small size of the evaluated 
cohorts, definitive conclusions could not be drawn 
regarding the actual impact of chromosome 8 abnormalities 
in CLL patients harboring TP53abs. In the present study we 
sought to obtain more insight into this issue by analyzing 
a series of 101 CLL patients with TP53abs, especially 
focusing on the potential prognostic value of 8p losses and 
8q gains in this poor prognostic group of patients.
RESULTS
Patients
A total of 101 patients carrying TP53 abnormalities 
were included in this study: 92 cases with del(17p) and 
9 additional cases with TP53 mutations. Demographic, 
clinical and biological data for the entire cohort are 
summarized in Table 1.
Chromosome 8 alterations 
Overall, 23/101 cases (22.8%) displayed 
chromosome 8 alterations. In detail, 11/75 patients 
(14.7%) showed 8p−, while 18/101 cases (17.8%) had 8q+ 
with different alteration patterns (Table 2). In 6/75 patients 
(8%) both abnormalities were concomitant; baseline 
characteristics of patients with concomitant 8p− and 8q+ 
are shown in Supplementary Table S1. Four of the cases 
with concomitant 8p− and 8q+ also presented two altered 
clones with shared FISH patterns (Table 2).
In 12/23 abnormal patients, chromosome 8 
alterations were identified prior to treatment initiation either 
at diagnosis or within the following 12 months (de novo). 
In contrast, in the remaining 11 cases chromosome 8 
analysis was performed later during the disease course 
(n = 10/11) or after treatment administration (n = 8/11) 
(median time to chromosome 8 analysis: 36 months, 
range: 9–132). In three of the latter cases, retrospective 
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FISH analysis of stored diagnostic material disclosed the 
presence of chromosome 8 alterations without del(17p); 
in one of these three cases, a different clonal distribution 
of the abnormal chromosome 8 clones was observed 
between the two time points (Supplementary Figure S1). 
Altogether, chromosome 8 alterations could be considered 
de novo in 65.2% of cases (15/23). Unfortunately, no 
previous cytogenetic studies from the remaining patients 
(8/23) were available to elucidate the acquisition pattern 
of chromosome 8 and TP53abs.  
For the purpose of this study, two types of 
comparisons were established: patients with 8p– vs. those 
with normal 8p (N-8p) and patients with 8q+ vs. those 
with normal 8q (N-8q).
Other cytogenetic abnormalities
At the time of chromosome 8 analysis by FISH, 
48.3% of patients presented del(13q), 12.9% trisomy 12 
and 5.7% del(11q). Among the 66 patients with available 
CBA, 53 (80.3%) presented an abnormal karyotype and 31 
(47%) showed a complex karyotype (CK).
When comparing cases with 8p− or 8q+ versus 
those with N-8p or N-8q, respectively, no differences 
regarding del(13q), trisomy 12 and del(11q) frequencies 
were detected. Both the 8p− and the 8q+ groups carried a 
higher median percentage of 17p-deleted cells compared 
to cases with normal chromosome 8, although differences 
were only significant for the 8p− vs. N-8p comparison 
Table 1: Baseline characteristics of patients at diagnosis and last follow-up
Patients characteristics (n = 101)  
Age at diagnosis 64 (42–87)
Male 69 (68.3%)
Diagnosis  
MBL* 6 (5.9%)
CLL 95 (94.1%)
Binet stage** (n = 90)  
A 57 (63.3%)
B 23 (25.6%)
C 10 (11.1%)
B-symptoms (n = 67) 6 (9%)
Adenopathies (n = 71) 37 (52.1%)
Splenomegaly (n = 68) 12 (17.6%)
Hepatomegaly (n = 68) 6 (8.8%)
Absolute white blood cell count (× 109/L) (n = 71) 20 (3.8–372)
Absolute lymphocyte count (× 109/L) (n = 68) 15 (1–369)
Hemoglobin (g/dL) (n = 68) 13.8 (7–18)
Platelets (×109/L) (n = 68) 196 (2–356)
Lactate dehydrogenase (IU/L) (n = 64) 335 (180–959)
Beta-2 microglobulin (mg/L) (n = 59) 2.4 (1–8.4)
Unmutated IGHV  (n = 32) 27 (84.4%)
Mutated NOTCH1 (n = 19) 2 (10.5%)
Last follow-up  
Treated patients (n = 97) 81 (83.5%)
Time to first treatment (months, 95% CI) (n = 96) 23 (14–33)
Deaths 66 (65.3%) 
Overall survival (months, 95% CI) (n = 99) 88 (67–108)
Follow-up (months) 62 (0–201)
Values are given as median (range) or number (%). Hemoglobin is expressed as mean (range). 
*Although 6 patients were diagnosed as MBL (monoclonal B-cell lymphocytosis), all of them had already progressed to CLL 
at the time of study. **Some centers only provided information regarding the Binet stage without the physical examination 
and the analytical parameters. 
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(87% vs. 50%, P = 0.001; 70% vs. 48%, P = 0.07). As for 
CBA, both the 8p− and the 8q+ group displayed a higher 
median number of chromosomal alterations (7 vs. 3, 
P = 0.041 and 6.5 vs. 2, P =  0.001 respectively), therefore 
displaying a higher frequency of CK (100% vs. 45.9%, 
P = 0.006 and 85.7% vs. 36.5%, P = 0.002 respectively) 
compared to N-8p and N-8q cases. 
Demographic and baseline characteristics
When comparing 8p− vs. N-8p and 8q+ vs. N-8q 
cases the only statistically important differences concerned 
female prevalence (63.6% vs. 31.3%, P = 0.049) and 
lower hemoglobin levels (12.8 vs. 14 g/dL, P = 0.018) in 
the 8p− group. 
Therapy
Overall, with a median follow up of 62 months 
(0–201), 81/97 cases (83.5%) had received treatment. Of 
note, in 34/93 cases (36.6%), therapy was administered prior 
to chromosome 8 testing. In 17/23 cases with 8p− and/or 8q+ 
(73.9%), these alterations were observed before treatment, 
whereas in the remaining six patients therapy-related 
acquisition could not be formally excluded as no relevant 
sample from the time of diagnosis was available for testing.
Among treatment-naïve cases, both 8p− and 8q+ 
groups exhibited a shorter time to first treatment (TTFT; 
11 vs. 45 months for 8p− vs. N-8p and 15 vs. 45 months 
for 8q+ vs. N-8q) although differences did not reach 
statistical significance. 
Table 2: Chromosome banding analysis and FISH results in patients with alterations of chromosome 8
 Chromosome Banding Analysis FISH
ID Karyotype
% 
del(17p)
Chromosome 8 alteration
% FISH patterns*
1 46,XX,del(8)(p21),add(10)(q26),add(17)(p13),+2ac[5]/47,XX,+12,add(17)(p13),del(18)(q21),add(22)(q13)[3] 80 20 1O2G
8p-
2 − 95 75 1O2G
3 46,XX,add(6)(q24),add(14)(q32.3),i(17)(q10)[6]/46,XX[8] 95 75 1O2G
4 48,X,-X,-17,+4mar[13]/44,X,-X,del(6)(q23),-9,-13,-17,-21,+3mar[3]/46,XX[4] 86 50 1O2G
5 45,XY,-5,-9,-15,add(17)(p13),+18,-21,+2mar[13]/46,XY[37] 70 17 1O2G
6 44,X,-X,-6,der(13;15)(q10;q10),add(17)(p13),-20,+mar[13]/46,XX[7] 95 23/10 1O2G/1O3G
8p- and 8q+
7 46,X,der(X),add(8)(p23),del(13)(q12q22),add(17)(p13)[11]/46,XX[13] 10 32 1O3G
8 − 95 64 1O3G
9
45,XY,add(3)(q29),del(4)(q26q35),der(7)(1p36→1p32::7p22®7q32::15q22→15q26), 
-8,der(9),del(13)(q21q34),-15,-17,-18,+19, add(19)(p13),+2mar,+ac[17]/46,XY[3]
78 34/21 1O3G/2O3G
10 − 95 66/31 1O3G/1O2G
11 45,XY,add(6)(q22),del(11)(q11q22),-17[15]/44,XY,add(6)(q22),del(11)(q11q22),-17,-20,-22,+mar[2] 87 40/24 1O3G/1O2G
12
46,XX,del(13)(q14q21)[2]/45,X,-X,del(13)(q14q21)[3]/45,XX,add(3)(q27),t(9;10)(q21;q22), 
+12,der(12)t(12;17)(q11;p11),del(13)(q14q21),-14,-17[7]/46,XX[8]
70 62 2O3G
8q+
13 46,XY[30] 14 88 2O3G
14 46,XY[13] 80 82 2O3G
15 47,XY,+12[8]/46,XY,add(1)(p34),add(2)(q34),t(11;22)(p14;q11),+12,-22[15]/46,XY[11] 75 18 2O3G
16 45,XY,add(6)(p11),-22[13]/46,XY,i(17)(q10)[5]/46,XY[16] 16 57 2O3G
17 45,XY,del(6)(q?),-9,add(14)(q32),-22,+mar[9]/46,XY,del(6)(q?),add(17)(p13),add(19)(q13)[21] 55 23 2O3G
18 43,X,-X,del(2)(p15),+4,-7,add(11)(q21),-12,-13,add(14)(q32),add(17)(p11.2)[6]/46,XX[9] 19 14 2O3G
19 − 70 66 2O4G
20 − 90 81 2OnG
21#
43-44,X,-Y,add(2)(q37),dic(3;11)(p21;q23),-8,add(8)(q24),add(16)(q24),-17,add(17)(p13), 
-18,+mar1,+mar2[cp18]/46,XY[11]
68 18 3G
22#
45,XY,-15,add(17)(p13)[7]/45,XY,-15,add(17)(p13),add(21)(p13)[5]/ 
44,XY,der(3)t(3;4)(p26;q21),-4,-15,add(17)(p13)[2]/46,XY[10]
53 15 3G
23# 42,X,-Y,del(4)(p12p15),-8,add(8)(q24),-13,add(14)(p13),-15,-17,add(21)(p13),+mar[17]/46,XY[3] 38 77 3G
*O: LPL (8p21) signal in orange, G: MYC (8q24) signal in green. 
#Only the MYC probe was analyzed.
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Survival analysis 
With a median follow-up of 62 months 
(range: 0–201), 35 patients (34.6%) remained alive. Ten-
year survival analysis revealed a significant shorter median 
OS for both 8p− and 8q+ patients compared with N-8p 
and N-8q group respectively (41 vs. 94 months; P = 0.002 
and 38 vs. 92 months; P = 0.012 respectively) (Figure 1, 
Table 3). Interestingly, even though the number of cases 
with concomitant 8p− and 8q+ was low (n = 6), they 
exhibited a significant shorter OS compared to patients 
with isolated chromosome 8 alterations (26 vs. 88 months, 
P = 0.016). An elevated percentage of 17p-deleted cells 
also was related to inferior outcome, with the optimal cut-
off being ≥80% of deleted cells (P < 0.001). 
Regarding chromosomal abnormalities detected by 
CBA, patients with CK exhibited a shorter OS (P = 0.009), 
which was independent of the presence or absence of 8q+ 
(48 vs. 62 months, P = 0.538) (Figure 1). Similar results 
were obtained when cases analyzed after treatment were 
excluded from the statistical analysis (Supplementary 
Figure S2). On multivariate analysis including 8q+, ≥ 80% 
of 17p-deleted cells and CK only ≥ 80% of 17p-deleted 
cells (P = 0.046, HR = 2.2) and CK (P = 0.027, HR = 2.5) 
retained independent significance (Table 3). Multivariate 
analysis including 8p− cases could not be performed due 
to the low number of patients with available data from 
both CBA and 8p status.
DISCUSSION
Mounting evidence suggests that within CLL 
patients with TP53abs additional genetic features 
may influence the clinical outcome [17, 22, 23]. More 
specifically, alterations in chromosome 8 are more 
frequently detected in CLL patients with TP53abs and 
have been proposed as potentially prognostic markers in 
this aggressive group. Nevertheless, large studies focusing 
on the characterization and clinical outcome of this subset 
of patients are lacking. In order to address this issue, we 
retrospectively analyzed 101 CLL patients with TP53abs 
from our collaborating institutions. The frequency of 
8p− was 14.7%, whereas 8q+ was detected in 17.8% 
of patients, being concomitant in 30% of cases with 
chromosome 8 alterations. To the best of our knowledge, 
this is the largest cohort of patients with TP53abs 
confirming the enrichment of chromosome 8 abnormalities 
in this disease subgroup. The frequencies reported herein 
are lower than those in previous studies, which, however, 
concerned significantly smaller cohorts, thus raising the 
possibility of selection bias [17, 19, 20]. 
The high percentage of de novo chromosome 
8 alterations reported here suggests that 8p− and 8q+ 
can occur early in the course of the disease. This is 
in agreement with earlier reports of 8p− and 8q+ in 
treatment-naïve patients [20, 21]. Indeed, subsequent 
whole-exome sequencing studies analyzing clonal 
heterogeneity also suggested 8p− and 8q+ as early events 
during CLL development, whereas TP53 aberrations seem 
to appear later in the course of the disease [24].
Regarding the clinical characteristics of patients 
with alterations in chromosome 8 at diagnosis, no 
significant differences could be identified between groups 
except for gender distribution and hemoglobin levels. 
As for the genetic characteristics, we found a higher 
percentage of 17p-deleted nuclei in patients with 8p− or 
8q+. Furthermore, in accordance with previous reports, a 
higher rate of CK was associated with both chromosome 
8 abnormalities (8p− and 8q+) [25, 26]. Concerning 
clinical outcome, even though both 8p− and 8q+ exhibited 
a shorter TTFT, differences did not reach statistical 
significance. Nonetheless, a decreased OS was observed 
for both 8p− and 8q+, with concomitant 8p− and 8q+ 
cases exhibiting the worst outcome. Concerning patients 
with isolated 8p− or 8q+, given the small number of cases, 
we could not statistically assess their potential impact on 
survival. Our findings indicate that co-existence of 8p− 
and 8q+ may have a potential clinical impact in CLL and 
should be better evaluated in future research. However, 
further studies in larger patient cohorts are needed to 
discern the clinical consequences of isolated 8p− or 8q+.   
Karyotypic complexity has been reported to be 
significantly associated with TP53abs [7, 25, 27] and 
to have a negative impact on survival even within this 
aggressive subset of patients [8, 23, 27]. Our present 
study confirms and significantly extends previous reports 
highlighting the impact of genetic instability in the 
pathogenesis of the disease. Indeed, although 89% of cases 
with 8p− and/or 8q+ showed a CK, in the multivariate 
analysis only karyotypic complexity and the percentage of 
17p-deleted nuclei maintained the statistical significance. 
This finding suggests that CK rather than chromosome 8 
alterations is responsible for the dismal clinical evolution 
of these patients. Chromosome 8 alterations could reflect 
underlying genomic instability leading to karyotypic 
complexity and could suggest the implication of different 
genes such as MYC in 8q+ cases and tumor suppressors 
such as TNFRSF10A/B (8p21) in 8p− cases [20, 28]. 
Notably, however, almost 40% of cases with CK did not 
show 8p− or 8q+ but displayed the same poor outcome as 
those with chromosome 8 alterations and CK. 
In conclusion, our results highlight the association 
of chromosome 8 abnormalities with CK amongst CLL 
patients with TP53abs, while also revealing that CK 
can further aggravate the prognosis of this aggressive 
subgroup. These findings further underscore the relevance 
of chromosome banding analysis, which has the potential 
to refine prognosis even amongst cases with altered TP53.
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MATERIALS AND METHODS
Patient selection
For the purpose of this study, we evaluated CLL 
patients with TP53abs and available Carnoy fixed tumoral 
cells from 17 collaborating institutions in Spain and 
Greece (Supplementary Figure S3). All patients met the 
iwCLL diagnostic criteria [29]. A total of 101 patients 
carrying TP53 abnormalities were identified: 92 cases with 
del(17p) detected by FISH and 9 additional cases with 
TP53 mutations identified by Sanger sequencing. Of note, 
six patients had been diagnosed of CLL-like monoclonal 
B cell lymphocytosis (MBL) but had already progressed 
to CLL at the time of the study. Treatment initiation and 
response assessment followed standard criteria [29, 30]. 
The study was performed in accordance with national and 
international guidelines (Professional Code of Conduct, 
Table 3: Univariate and multivariate analysis on ten-year overall survival
Variable
 Univariate Multivariate
 Median OS (95% CI) in months P-value
Hazard ratio 
(95% CI) P-value
Loss of 8p by FISH
8p− 41 (24–58) 0.002
NA NA
N-8p 94 (60–127)  
Gain of 8q by FISH
8q+ 38 (0–85) 0.012
1.23 (0.52–2.90) 0.642
N-8q 92 (84–100)  
Complex karyotype
Yes 62 (40–83) 0.009
2.47 (1.11–5.49) 0.027
No NR  
Percentage of cells with 17p 
deletion
≥ 80% 41 (21–61) < 0.001
2.21 (1.02–4.80) 0.046
< 80% 94 (60–129)  
NA, not assessed; NR, not reached.
Figure 1: Kaplan-Meier plots for ten-year OS in patients carrying (A) 8p−, (B) 8q+, (C) CK, (D) ≥80% 17p deleted 
cells and (E) CK with 8q+ or N-8q.
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Declaration of Helsinki) and approved by the Ethics 
Committee of Hospital del Mar, Barcelona (2013/5093/I). 
Fluorescence in situ hybridization and 
chromosome banding analysis
Chromosome 8 alterations were assessed in the 
same Carnoy fixed tumoral cells (peripheral blood or bone 
marrow) which were used for the detection of TP53abs. 
Several samples were obtained from Parc de Salut MAR 
Biobank (MARBiobanc), Barcelona. The median time 
from diagnosis to study of chromosome 8 abnormalities 
was 15 months (range: 0–145) and 36.6% of the patients 
had received treatment prior to the analysis. Commercial 
FISH probes covering LPL (8p21) and MYC (8q24) genes 
(Abbott Molecular, Abbott Park, IL) were used in 75 and 
101 patients, respectively. Moreover, data from routine 
FISH (D13S319, CEP12 and ATM) and CBA (72 h + TPA 
and/or CpG + IL2) were also available in 91 and 66 cases, 
respectively. Complex karyotypes (CK) were defined 
as the presence of three or more numerical/structural 
chromosomal abnormalities.
Statistical analysis
Chi-square or Fisher exact tests were employed 
for discrete variables, while comparisons of continuous 
variables were assessed by the Mann–Whitney test. TTFT 
was defined as the time from diagnosis to the beginning 
of treatment and OS as the time from diagnosis to death 
or last follow-up. Both parameters were evaluated using 
Kaplan-Meier plots within the first ten years of follow-up. 
The effect of different covariates was assessed employing 
the log-rank test. Multivariate analysis according to the 
Cox proportional hazards regression model was used to 
evaluate the maintenance of their independent predictive 
value. Statistical analyses were performed using SPSS v.22 
software (SPSS Inc, Chicago, IL, USA). P-values below 
0.05 were considered statistically significant. The optimal 
cut-off value for the percentage of cells harboring del(17p) 
was assessed using Maximally Selected Rank Statistics in R.
ACKNOWLEDGMENTS AND GRANT 
SUPPORT    
The authors want to thank Marta Salido, Carme 
Melero, Ana Batlle, Mª Ángeles Piñán, Alicia Rodríguez 
and George Papaioannou for their contribution to the 
study providing clinical or laboratory data, Sergi Mojal 
for statistical review, and Grupo Cooperativo Español 
de Citogenética Hematológica (GCECGH) and Grupo 
Español de Leucemia Linfática Crónica (GELLC). 
This work has been supported by the following 
grants: PI11/01621, PI15/00437, RD09/0076/00036, 
RD12/0036/0044, RD12/0036/0069 and PT13/0010/0005 
FEDER, Instituto de Salud Carlos III, Spanish Ministry 
of Economy and Competitiveness; 2014/SGR585 from 
Generalitat de Catalunya; “Xarxa de Bancs de tumors” 
sponsored by Pla Director d’Oncologia de Catalunya 
(XBTC) and Fundació La Caixa; the Swedish Cancer 
Society, the Swedish Research Council, the Lion’s 
Cancer Research Foundation, and Selander’s Foundation, 
Uppsala; H2020 “AEGLE, An analytics framework for 
integrated and personalized healthcare services in Europe” 
by the EU.
CONFLICTS OF INTEREST 
The authors made no disclosure of conflicts of 
interest.
Authors’ contributions 
A.P. and B.E. designed the research study. G.B., 
A.P. and B.E. provided patients data, analyzed the data 
and wrote the manuscript. P.B., A.X. and K.S. provided 
patients information, performed data analysis and critical 
discussion of the results. A.A., M.D.G., R.C., M.R.R., 
M.O., M.J.C., E.L., M.T.V., J.G., C.M.L., A.V., J.C., A.A., 
E.G., E.A., E.S., J.M.H., F.O., D.R., A.F., D.I., M.G., F.B. 
and P.A. provided patient data. All authors read the last 
version of the manuscript. 
REFERENCES
1. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, 
Bullinger L, Döhner K, Bentz M, Lichter P. Genomic 
aberrations and survival in chronic lymphocytic leukemia. 
N Engl J Med. 2000; 343:1910–1916.
2. Van Dyke D, Werner L, Rassenti L, Neuberg D, Ghia E, 
Heerema N, Dal Cin P, Dell Aquila M, Sreekantaiah C, 
Greaves A, Kipps T, Kay N. The Dohner fluorescence 
in situ hybridization prognostic classification of chronic 
lymphocytic leukaemia (CLL): the CLL Research 
Consortium experience. Br J Haematol. 2016; 173:105–113.
3. Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, 
Soussi T, Helfrich H, Heuberger M, Hoth P, Fuge M, 
Denzel T, Häbe S, Malcikova J et al. TP53 mutation profile 
in chronic lymphocytic leukemia: evidence for a disease 
specific profile from a comprehensive analysis of 268 
mutations. Leukemia. 2010; 24:2072–2079.
4. Baliakas P, Hadzidimitriou A, Sutton L, Rossi D, Minga E, 
Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, 
Davis Z, Tausch E, Stalika E, Kantorova B et al. Recurrent 
mutations refine prognosis in chronic lymphocytic 
leukemia. Leukemia. 2015; 29:329–336.
5. Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, 
Pinyol M, Jares P, Navarro A, Martin-Garcia D, Bea S, 
Oncotarget80923www.impactjournals.com/oncotarget
Salaverria I, Oldreive C, Aymerich M et al. Clinical impact 
of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, 
and ATM mutations in chronic lymphocytic leukemia. 
Blood. 2016; 127:2122–2130.
 6. Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A, 
Sarno A, Groner S, Mertens D, Busch R, Hallek M, 
Dohner H, Stilgenbauer S. Detailed analysis of p53 pathway 
defects in fludarabine-refractory chronic lymphocytic 
leukemia (CLL): dissecting the contribution of 17p deletion, 
TP53 mutation, p53-p21 dysfunction, and miR34a in a 
prospective clinical trial. Blood. 2009; 114:2589–2597.
 7. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, 
Wu L, Kern W, Haferlach T, Haferlach C. The detection 
of TP53 mutations in chronic lymphocytic leukemia 
independently predicts rapid disease progression and is 
highly correlated with a complex aberrant karyotype. 
Leukemia. 2009; 23:117–124.
 8. Baliakas P, Iskas M, Gardiner A, Davis Z, Plevova K, 
Nguyen-Khac F, Malcikova J, Anagnostopoulos A, Glide S, 
Mould S, Stepanovska K, Brejcha M, Belessi C et al. 
Chromosomal translocations and karyotype complexity in 
chronic lymphocytic leukemia: A systematic reappraisal of 
classic cytogenetic data. Am J Hematol. 2014; 89:249–255.
 9. Puiggros A, Puigdecanet E, Salido M, Ferrer A, Abella E, 
Gimeno E, Nonell L, Herranz M, Galván A, Rodríguez-
Rivera M, Melero C, Pairet S, Bellosillo B et al. 
Genomic arrays in chronic lymphocytic leukemia routine 
clinical practice: are we ready to substitute conventional 
cytogenetics and fluorescence in situ hybridization 
techniques? Leuk Lymphoma. 2013; 54:986–995.
10. Jain N, O’Brien S. Initial treatment of CLL: integrating 
biology and functional status. Blood. 2015; 126:463–470.
11. Furman R, Sharman J, Coutre S, Cheson B, Pagel J, 
Hillmen P, Barrientos J, Zelenetz A, Kipps T, Flinn I, 
Ghia P, Eradat H, Ervin T et al. Idelalisib and rituximab 
in relapsed chronic lymphocytic leukemia. N Engl J Med. 
2014; 370:997–1007.
12. Byrd J, Furman R, Coutre S, Burger J, Blum K, Coleman M, 
Wierda W, Jones J, Zhao W, Heerema N, Johnson A, Shaw Y, 
Bilotti E et al. Three-year follow-up of treatment-naive and 
previously treated patients with CLL and SLL receiving 
single-agent ibrutinib. Blood. 2015; 125:2497–2506.
13. Farooqui M, Valdez J, Martyr S, Aue G, Saba N, 
Niemann C, Herman S, Tian X, Marti G, Soto S, Hughes T, 
Jones J, Lipsky A et al. Ibrutinib for previously untreated 
and relapsed or refractory chronic lymphocytic leukaemia 
with TP53 aberrations: a phase 2, single-arm trial. Lancet 
Oncol. 2015; 16:169–176.
14. Tam C, Shanafelt T, Wierda W, Abruzzo L, Van Dyke D, 
O’Brien S, Ferrajoli A, Lerner S, Lynn A, Kay N, 
Keating M. De novo deletion 17p13.1 chronic lymphocytic 
leukemia shows significant clinical heterogeneity: the M. 
D. Anderson and Mayo Clinic experience. Blood. 2009; 
114:957–964.
15. Best O, Gardiner A, Davis Z, Tracy I, Ibbotson R, Majid A, 
Dyer M, Oscier D. A subset of Binet stage A CLL patients 
with TP53 abnormalities and mutated IGHV genes have 
stable disease. Leukemia. 2009; 23:212–214.
16. Tyybäkinoja A, Vilpo J, Knuutila S. High-resolution 
oligonucleotide array-CGH pinpoints genes involved in 
cryptic losses in chronic lymphocytic leukemia. Cytogenet 
Genome Res. 2007; 118:8–12.
17. Forconi F, Rinaldi A, Kwee I, Sozzi E, Raspadori D, 
Rancoita P, Scandurra M, Rossi D, Deambrogi C, 
Capello D, Zucca E, Marconi D, Bomben R et al. Genome-
wide DNA analysis identifies recurrent imbalances 
predicting outcome in chronic lymphocytic leukaemia with 
17p deletion. Br J Haematol. 2008; 143:532–536.
18. O’Malley D, Giudice C, Chang A, Chang D, Barry T, 
Hibbard M, Chen R, Chen S. Comparison of array 
comparative genomic hybridization (aCGH) to FISH and 
cytogenetics in prognostic evaluation of chronic lymphocytic 
leukemia. Int J Lab Hematol. 2011; 33:238–244.
19. Rinaldi A, Mian M, Kwee I, Rossi D, Deambrogi C, 
Mensah A, Forconi F, Spina V, Cencini E, Drandi D, 
Ladetto M, Santachiara R, Marasca R et al. Genome-wide 
DNA profiling better defines the prognosis of chronic 
lymphocytic leukaemia. Br J Haematol. 2011; 154:590–599.
20. Brown J, Hanna M, Tesar B, Werner L, Pochet N, 
Asara J, Wang Y, dal Cin P, Fernandes S, Thompson C, 
MacConaill L, Wu C, Van de Peer Y et al. Integrative 
genomic analysis implicates gain of PIK3CA at 3q26 and 
MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer 
Res. 2012; 18:3791–3802.
21. Houldsworth J, Guttapalli A, Thodima V, Yan X, 
Mendiratta G, Zielonka T, Nanjangud G, Chen W, Patil S, 
Mato A, Brown J, Rai K, Chiorazzi N, et al. Genomic 
imbalance defines three prognostic groups for risk 
stratification of patients with chronic lymphocytic leukemia. 
Leuk Lymphoma. 2013; 55:920–928.
22. Delgado J, Espinet B, Oliveira A, Abrisqueta P, de la 
Serna J, Collado R, Loscertales J, Lopez M, Hernandez-
Rivas J, Ferra C, Ramirez A, Roncero J, Lopez C et al. 
Chronic lymphocytic leukaemia with 17p deletion: a 
retrospective analysis of prognostic factors and therapy 
results. Br J Haematol. 2012; 157:67–74.
23. Delgado J, Salaverria I, Baumann T, Martinez-Trillos A, 
Lee E, Jimenez L, Navarro A, Royo C, Santacruz R, 
Lopez C, Payer A, Colado E, Gonzalez M et al. Genomic 
complexity and IGHV mutational status are key predictors 
of outcome of chronic lymphocytic leukemia patients with 
TP53 disruption. Haematologica. 2014; 99: e231-e234.
24. Landau D, Tausch E, Taylor-Weiner A, Stewart C, Reiter J, 
Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, 
Carter S, Cibulskis K, Mertens D et al. Mutations driving 
CLL and their evolution in progression and relapse. Nature. 
2015; 526:525–530.
25. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. 
Comprehensive genetic characterization of CLL: a study 
Oncotarget80924www.impactjournals.com/oncotarget
on 506 cases analysed with chromosome banding analysis, 
interphase FISH, IgVH status and immunophenotyping. 
Leukemia. 2007; 21:2442–2451.
26. Travella A, Ripollés L, Aventin A, Rodríguez A, Bezares R, 
Caballín M, Slavutsky I. Structural alterations in chronic 
lymphocytic leukaemia. Cytogenetic and FISH analysis. 
Hematol Oncol. 2013; 31:79–87.
27. Jaglowski S, Ruppert A, Heerema N, Bingman A, Flynn J, 
Grever M, Jones J, Elder P, Devine S, Byrd J, Andritsos L. 
Complex karyotype predicts for inferior outcomes following 
reduced-intensity conditioning allogeneic transplant for 
chronic lymphocytic leukaemia. Br J Haematol. 2012; 
159:82–87.
28. Rubio-Moscardo F, Blesa D, Mestre C, Siebert R, Balasas T, 
Benito A, Rosenwald A, Climent J, Martinez JI, Schilhabel M, 
Karran EL, Gesk S, Esteller M et al. Characterization 
of 8p21.3 chromosomal deletions in B-cell lymphoma: 
TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent 
tumor suppressor genes. Blood. 2005; 106:3214–3222.
29. Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, 
Dighiero G, Dohner H, Hillmen P, Keating M, Montserrat E, 
Rai K, Kipps T. Guidelines for the diagnosis and treatment 
of chronic lymphocytic leukemia: a report from the 
International Workshop on Chronic Lymphocytic Leukemia 
updating the National Cancer Institute-Working Group 1996 
guidelines. Blood. 2008; 111:5446–5456.
30. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, 
O’Brien S, Rai KR. National Cancer Institute-sponsored 
Working Group guidelines for chronic lymphocytic 
leukemia: revised guidelines for diagnosis and treatment. 
Blood. 1996; 87:4990–4997. 
